Gordon Sandford
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gordon Sandford has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Gary H. Posner
Department of Chemistry, The Johns Hopkins University, 3400 N. Charles Street, Baltimore, Maryland 21218, United States
1 shared publication - Gary S. Hayward
Viral Oncology Program, The Johns Hopkins School of Medicine, Baltimore, Maryland, USA
1 shared publication - Michael Forman
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
1 shared publication - Ran He
Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA
1 shared publication - Ravit Arav-Boger
Department of Pediatrics, Division of Infectious Disease, Medical College of Wisconsin, Milwaukee, WI, 53226, USA
1 shared publication William H Burns
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
1 shared publication
Latest Publications
- Open Access
- 26 January 2011
- Published by Springer Nature in Virology Journal
- Vol. 8 (1) , 40
Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors
Recombinant Towne CMV expressing luciferase under the control of CMV-DNA polymerase (POL) or the late pp28 (UL99) promoters were evaluated for potential application in high-throughput screening of anti-viral compounds. POL-and pp28-luciferase displayed maximal expression 48 and 72 hours post infection, respectively. The pp28-luciferase virus achieved a wider dynamic range of luciferase expression (6-7 logs) and was selected for testing of inhibition by five anti-viral compounds. Luciferase expression highly correlated with plaque reduction and real-time PCR. The pp28-luciferase reporter system is rapid, reproducible, and highly sensitive. It may be applied to screening of novel anti-CMV compounds.
- 26 January 2011
- Published by Springer Nature in Virology Journal
- Vol. 8 (1) , 40
Open AccessRecombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors
Recombinant Towne CMV expressing luciferase under the control of CMV-DNA polymerase (POL) or the late pp28 (UL99) promoters were evaluated for potential application in high-throughput screening of anti-viral compounds. POL-and pp28-luciferase displayed maximal expression 48 and 72 hours post infection, respectively. The pp28-luciferase virus achieved a wider dynamic range of luciferase expression (6-7 logs) and was selected for testing of inhibition by five anti-viral compounds. Luciferase expression highly correlated with plaque reduction and real-time PCR. The pp28-luciferase reporter system is rapid, reproducible, and highly sensitive. It may be applied to screening of novel anti-CMV compounds.